Dave Schubert

Dave is the SVP of Regulatory Affairs and Quality of Ventus Therapeutics. Dave has over 35 years of experience in regulatory, quality, drug, and process development. He was SVP of Regulatory and Quality at Carmot Therapeutics, responsible for regulatory and quality strategies for its three GLP-1/GIP dual agonist small molecule and peptide products. Carmot was acquired by Roche, where Dave worked most recently. Prior to that, he served as SVP at Chiasma. Dave is a protein chemist by training and was twice the head of CMC in the past, with wide-ranging GXP compliance experience supporting GLP, GCP, and GMP. Dave holds a B.S. from the University of New Hampshire.